Cullinan Oncology to Present New Preclinical Data for
CLN-619 is a MICA/B directed humanized IgG1 antibody being studied in a global Phase 1 clinical trial in patients with advanced solid tumors. Initial...
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2023-03-15, 03:39
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2023-02-14, 07:09
Cullinan Oncology Licenses U.S. Rights to the First
CAMBRIDGE, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) and Harbour BioMed (HKEX: 02142) today announced that Cullinan...
